Latest Probiotics News

EZZ Life Science Holdings marked a pivotal quarter with the launch of its EZZDAY brand in the US, a significant Southeast Asia distribution agreement, and expanded domestic retail presence, driving a 46% jump in customer receipts.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

Terragen Holdings has been granted a US patent for its microbial feed supplements, reinforcing its position in the animal probiotics market and supporting plans for US market entry.

Biome Australia has reported record-breaking sales revenue for FY25, driven by strong domestic demand and promising international expansion. The company is on track to deliver its first full-year net profit and meet ambitious growth targets.

EZZ Life Science has launched its US-focused brand EZZDAY with four FDA-registered supplements, marking a major step in its international growth strategy. The company has also begun US-based manufacturing and opened an online store to target American consumers.

EVE Health Group has launched a $1.5 million capital raise alongside the acquisition of biotech firm Nextract, aiming to expand its footprint in health and pharmaceutical products focused on erectile dysfunction and period pain.

Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.

Terragen Holdings has launched its new probiotic products for ruminants, initiated multiple key trials including methane mitigation and crop yield studies, and secured a US patent allowance, positioning itself for global market expansion.

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Biome Australia is set to expand its Activated Probiotics range with two new products targeting vaginal health and perinatal care, tapping into a booming women’s health supplements market.

Biome Australia Limited has reported its first-ever net profit of $433,395 for the half-year ended December 2024, alongside a 47.4% increase in revenue driven by strong sales of its Activated Probiotics.